BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35752351)

  • 1. Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.
    Shalom B; Farago M; Salaymeh Y; Sebban S; Risling M; Pikarsky E; Katzav S
    Cell Signal; 2022 Sep; 97():110395. PubMed ID: 35752351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.
    Salaymeh Y; Farago M; Sebban S; Shalom B; Pikarsky E; Katzav S
    Life Sci Alliance; 2020 May; 3(5):. PubMed ID: 32277014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion.
    Sebban S; Farago M; Rabinovich S; Lazer G; Idelchuck Y; Ilan L; Pikarsky E; Katzav S
    Oncotarget; 2014 Oct; 5(19):9214-26. PubMed ID: 25313137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis.
    Lazer G; Idelchuk Y; Schapira V; Pikarsky E; Katzav S
    J Pathol; 2009 Sep; 219(1):25-34. PubMed ID: 19533802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.
    Katzav S
    Oncotarget; 2015 Oct; 6(30):28731-42. PubMed ID: 26353933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies.
    Katzav S
    Cancer Lett; 2007 Oct; 255(2):241-54. PubMed ID: 17590270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vav1 Promotes B-Cell Lymphoma Development.
    Shalom B; Farago M; Salaymeh Y; Sebban S; Pikarsky E; Katzav S
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin is an oncogenic Vav1- but not wild-type Vav1-responsive gene: implications for fibroblast transformation.
    Schapira V; Lazer G; Katzav S
    Cancer Res; 2006 Jun; 66(12):6183-91. PubMed ID: 16778192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of Sam68 with Vav1 contributes to tumorigenesis.
    Lazer G; Pe'er L; Schapira V; Richard S; Katzav S
    Cell Signal; 2007 Dec; 19(12):2479-86. PubMed ID: 17855053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
    Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
    Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Oncogenic Potential of VAV1 in Human Cancer: Lessons from Mouse Models.
    Shalom B; Salaymeh Y; Risling M; Katzav S
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vav1: a hematopoietic signal transduction molecule involved in human malignancies.
    Katzav S
    Int J Biochem Cell Biol; 2009 Jun; 41(6):1245-8. PubMed ID: 19100858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fusion oncogene VAV1-MYO1F triggers aberrant T-cell receptor signaling in vivo and drives peripheral T-cell lymphoma in mice.
    Morrish E; Wartewig T; Kratzert A; Rosenbaum M; Steiger K; Ruland J
    Eur J Immunol; 2023 Mar; 53(3):e2250147. PubMed ID: 36541400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of Vav1 adaptor region reveals a new oncogenic activation.
    Razanadrakoto L; Cormier F; Laurienté V; Dondi E; Gardano L; Katzav S; Guittat L; Varin-Blank N
    Oncotarget; 2015 Feb; 6(4):2524-37. PubMed ID: 25426554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
    Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
    PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.
    Robles-Valero J; Fernández-Nevado L; Cuadrado M; Lorenzo-Martín LF; Fernández-Pisonero I; Abad A; Redín E; Montuenga L; Martín-Zanca D; Bigas A; Mallo M; Dosil M; Bustelo XR
    Mol Oncol; 2022 Oct; 16(19):3533-3553. PubMed ID: 35895495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses.
    Ruiz S; Santos E; Bustelo XR
    Mol Cell Biol; 2007 Dec; 27(23):8127-42. PubMed ID: 17923690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation.
    Ilan L; Katzav S
    PLoS One; 2012; 7(1):e29939. PubMed ID: 22253833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.